600276 恒瑞医药
午间休市 10-15 11:29:59
资讯
新帖
简况
港股异动 | 恒瑞医药(01276)涨超3% 自研治疗AD药物SHR-3201注射液获批开展临床试验
智通财经 · 09:58
港股异动 | 恒瑞医药(01276)涨超3% 自研治疗AD药物SHR-3201注射液获批开展临床试验
恒瑞医药(600276.SH)：SHR-3201注射液获得药物临床试验批准通知书
智通财经 · 10-13 17:04
恒瑞医药(600276.SH)：SHR-3201注射液获得药物临床试验批准通知书
公募首份三季报出炉，南方港股医药大幅加仓凯莱英、药明康德、恒瑞医药
每日经济新闻 · 10-13 12:19
公募首份三季报出炉，南方港股医药大幅加仓凯莱英、药明康德、恒瑞医药
广发证券：维持恒瑞医药“买入”评级，SHR-1139银屑病Ⅱ期数据积极
同花顺 · 10-12 13:46
广发证券：维持恒瑞医药“买入”评级，SHR-1139银屑病Ⅱ期数据积极
SHR-1139银屑病Ⅱ期数据积极，广发证券：维持恒瑞医药“买入”评级
同花顺 · 10-12 13:45
SHR-1139银屑病Ⅱ期数据积极，广发证券：维持恒瑞医药“买入”评级
花旗集团在恒瑞医药的H股好仓比例上升0.35%至5.24%
南方财经网 · 10-09
花旗集团在恒瑞医药的H股好仓比例上升0.35%至5.24%
阿斯利康两款重磅ADC药物在华获批新适应证；恒瑞医药第二款自主研发的创新药向欧盟递交上市申请丨医药早参
每日经济新闻 · 10-09
阿斯利康两款重磅ADC药物在华获批新适应证；恒瑞医药第二款自主研发的创新药向欧盟递交上市申请丨医药早参
恒瑞医药（01276）：氟唑帕利胶囊上市许可申请获欧洲药品管理局确认并受理
金吾财讯 · 10-08
恒瑞医药（01276）：氟唑帕利胶囊上市许可申请获欧洲药品管理局确认并受理
贝莱德在恒瑞医药的H股好仓比例上升0.71%至6.37%
南方财经网 · 10-08
贝莱德在恒瑞医药的H股好仓比例上升0.71%至6.37%
恒瑞医药(01276)截至9月末累计回购58.5万股A股
智通财经 · 10-08
恒瑞医药(01276)截至9月末累计回购58.5万股A股
大行评级丨小摩：恒瑞医药正加强免疫学业务发展，维持“增持”评级
格隆汇 · 10-08
大行评级丨小摩：恒瑞医药正加强免疫学业务发展，维持“增持”评级
小摩：维持恒瑞医药“增持”评级 目标价65港元 EADV数据反映公司加强免疫学业务发展
同花顺 · 10-07
小摩：维持恒瑞医药“增持”评级 目标价65港元 EADV数据反映公司加强免疫学业务发展
恒瑞医药（01276）由跌转涨逾1% 小摩料其明年将有至少4款免疫学管线药物获批
金吾财讯 · 10-07
恒瑞医药（01276）由跌转涨逾1% 小摩料其明年将有至少4款免疫学管线药物获批
瑞银集团在恒瑞医药的H股好仓比例下降0.58%至4.59%
南方财经网 · 10-02
瑞银集团在恒瑞医药的H股好仓比例下降0.58%至4.59%
16股今日获机构买入评级 5股上涨空间超20%
东方财富网 · 09-30
16股今日获机构买入评级 5股上涨空间超20%
大和：恒瑞医药(01276)与诺和诺德就HRS-1596达许可协议 交易总额及预付款均具吸引力
智通财经 · 09-30
大和：恒瑞医药(01276)与诺和诺德就HRS-1596达许可协议 交易总额及预付款均具吸引力
大摩：维持恒瑞医药(01276)“增持”评级 目标价82港元
智通财经 · 09-30
大摩：维持恒瑞医药(01276)“增持”评级 目标价82港元
花旗：上调恒瑞医药目标价至120港元 仍是重点推荐之一
同花顺 · 09-30
花旗：上调恒瑞医药目标价至120港元 仍是重点推荐之一
诺和诺德加仓减重赛道，26亿美元买下恒瑞医药周口服减肥药
第一财经 · 09-29
诺和诺德加仓减重赛道，26亿美元买下恒瑞医药周口服减肥药
加速出海！恒瑞医药口服GLP-1/GIP减重药授权诺和诺德，潜在交易额最高26亿美元
华尔街见闻 · 09-29
加速出海！恒瑞医药口服GLP-1/GIP减重药授权诺和诺德，潜在交易额最高26亿美元
暂无数据
公司概况
公司名称：
江苏恒瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是注射用卡瑞利珠单抗、羟乙磺酸达尔西利片、瑞维鲁胺片、海曲泊帕乙醇胺片、脯氨酸恒格列净片、碘佛醇注射液。
发行价格：
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":46.06,"timestamp":1792034999000,"preClose":45.49,"halted":0,"volume":33281252,"delay":0,"changeRate":0.0125,"floatShares":6379000000,"shares":6637000000,"eps":1.1642,"marketStatus":"午间休市","change":0.57,"latestTime":"10-15 11:29:59","open":44.99,"high":46.48,"low":44.89,"amount":1530000000,"amplitude":0.035,"askPrice":46.08,"askSize":51,"bidPrice":46.06,"bidSize":24,"shortable":0,"etf":0,"ttmEps":1.1642,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792040400000},"marketStatusCode":3,"adr":0,"adjPreClose":45.49,"symbolType":"stock","openAndCloseTimeList":[[1792027800000,1792035000000],[1792040400000,1792047600000]],"highLimit":50.04,"lowLimit":40.94,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":4.68,"roa":"--","peRate":39.563649,"roe":"8.04%","epsLYR":1.19,"committee":-0.509972,"marketValue":305709000000,"turnoverRate":0.0052,"status":0,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":47.96,"timestamp":1792037100003,"preClose":46.5,"halted":0,"volume":2690993,"delay":0,"premium":"-11.20"},"floatMarketCap":293817000000},"requestUrl":"/m/hq/s/600276/tweets","defaultTab":"tweets","newsList":[{"id":"2675371541","title":"港股异动 | 恒瑞医药(01276)涨超3% 自研治疗AD药物SHR-3201注射液获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2675371541","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675371541?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:58","pubTimestamp":1792029530,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，恒瑞医药(01276)涨超3%，截至发稿，涨2.97%，报47.8港元，成交额4134.91万港元。消息面上，恒瑞医药发布公告，近日，江苏恒瑞医药股份有限公司(以下简称“公司”)子公司北京盛迪医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于SHR-3201注射液的《药物临床试验批准通知书》，将于近期开展临床试验。SHR-3201注射液是公司自主研发治疗阿尔茨海默病(AD)的药物，可清除患者脑内的疾病生物标志物，延缓患者认知衰退。经查询，国内外尚无同类药物获批上市。截至目前，SHR-3201注射液相关项目累计研发投入约为4,880万元(未经审计)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1507455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","LU1655091616.SGD","LU2097828805.USD","LU2097828631.EUR","LU2580892789.USD","BK1191","LU2148510915.USD","LU2289578879.USD","VXUS","LU2328871848.SGD","LU1997245177.USD","BK0012","LU2543165471.USD","LU0405327148.USD","BK0183","BK0060","BK0028","LU2488822045.USD","IBBQ","LU1997244956.HKD","LU0359201885.HKD","600276","BK4588","LU1146622755.USD","LU1820825898.SGD","BK4585","IBBJ","LU2097828557.USD","MDTX","LU0405327494.USD","LU0359202008.SGD","LU1580142542.USD","BK0239","LU1997245094.SGD","BK0196","LU2495084118.USD","BK0188","LU2097828474.EUR","LU1064130708.USD","LU1969619763.USD","LU1064131003.USD","LU1781817850.SGD","LU2580892862.HKD","LU1328615791.USD","LU0359201612.USD","PSYK","01276","BMED","LU2097828714.EUR","LU1255011170.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675332404","title":"恒瑞医药(600276.SH)：SHR-3201注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2675332404","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675332404?lang=zh_cn&edition=full","pubTime":"2026-10-13 17:04","pubTimestamp":1791882254,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司北京盛迪医药有限公司收到国家药品监督管理局核准签发关于SHR-3201注射液的《药物临床试验批准通知书》，将于近期开展临床试验。申请的适应症：阿尔茨海默病。SHR-3201注射液是公司自主研发治疗AD的药物，可清除患者脑内的疾病生物标志物，延缓患者认知衰退。经查询，国内外尚无同类药物获批上市。截至目前，SHR-3201注射液相关项目累计研发投入约为4,880万元(未经审计)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1506485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2495084118.USD","LU2097828805.USD","LU1820825898.SGD","LU2289578879.USD","LU1064131003.USD","01276","LU0405327148.USD","LU2097828474.EUR","LU2543165471.USD","LU2148510915.USD","LU0359201885.HKD","LU2097828557.USD","LU1655091616.SGD","BK0028","IBBQ","BK0188","BMED","LU1146622755.USD","BK0060","LU1580142542.USD","LU1997245177.USD","LU2097828714.EUR","LU1997244956.HKD","LU1255011170.USD","LU1064130708.USD","BK1191","LU0359202008.SGD","BK0183","LU2328871848.SGD","BK0239","IBBJ","600276","LU1781817850.SGD","LU2488822045.USD","LU1328615791.USD","LU0405327494.USD","LU1023057109.AUD","LU1997245094.SGD","MDTX","BK0012","LU1969619763.USD","LU2580892862.HKD","LU2580892789.USD","LU2097828631.EUR","PSYK","LU0359201612.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675338091","title":"公募首份三季报出炉，南方港股医药大幅加仓凯莱英、药明康德、恒瑞医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2675338091","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675338091?lang=zh_cn&edition=full","pubTime":"2026-10-13 12:19","pubTimestamp":1791865173,"startTime":"0","endTime":"0","summary":"10月13日，证监会官网披露显示，南方港股医药行业混合发布2026年第三季度报告，这也是公募基金行业首份三季报。从该基金发布的季报来看，A、C份额季内净值增长率分别达到18.49%、17.73%，季内大幅加仓了凯莱英、药明康德、恒瑞医药等个股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610133893966047.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610133893966047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","KURE","LU2097828631.EUR","LU0405327494.USD","BK0183","IE00BPRC5H50.USD","LU1328615791.USD","600276","LU2580892862.HKD","BK0196","LU0348767384.USD","LU1997245177.USD","LU1997245094.SGD","BK0012","02359","BK0028","603259","LU1251922891.USD","LU0572944931.SGD","159718","06821","002821","LU2242644610.SGD","LU0052750758.USD","LU2148510915.USD","LU0348766576.USD","LU1580142542.USD","LU1046422090.SGD","LU1781817850.SGD","LU1655091616.SGD","LU1146622755.USD","BK1576","LU2097828474.EUR","LU2125910500.SGD","LU1934453819.USD","LU2543165471.USD","LU2289578879.USD","01276","IE00B5MMRT66.SGD","LU1255011170.USD","LU0456842615.SGD","LU1808992512.USD","LU1820825898.SGD","LU1979443071.USD","LU2580892789.USD","IE00B543WZ88.USD","BK1141","LU1064131003.USD","BK1191","LU0359202008.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674829773","title":"广发证券：维持恒瑞医药“买入”评级，SHR-1139银屑病Ⅱ期数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2674829773","media":"同花顺","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674829773?lang=zh_cn&edition=full","pubTime":"2026-10-12 13:46","pubTimestamp":1791783960,"startTime":"0","endTime":"0","summary":"10月12日，广发证券研报指出，恒瑞医药(600276.SH)SHR-1139银屑病Ⅱ期数据积极，具备全球best-in-disease潜力。该行预计公司26-28年EPS分别为1.40、1.70、2.06元/股。本次数据进一步验证SH ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261012/c680581971.shtml","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261012/c680581971.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674829776","title":"SHR-1139银屑病Ⅱ期数据积极，广发证券：维持恒瑞医药“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2674829776","media":"同花顺","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674829776?lang=zh_cn&edition=full","pubTime":"2026-10-12 13:45","pubTimestamp":1791783900,"startTime":"0","endTime":"0","summary":"10月12日，广发证券研报指出，恒瑞医药(01276.HK)SHR-1139银屑病Ⅱ期数据积极，具备全球best-in-disease潜力。该行预计公司26-28年EPS分别为1.40、1.70、2.06元/股。本次数据进一步验证SHR ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261012/c680581883.shtml","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261012/c680581883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674830351","title":"花旗集团在恒瑞医药的H股好仓比例上升0.35%至5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674830351","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674830351?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:18","pubTimestamp":1791537480,"startTime":"0","endTime":"0","summary":"南财智讯10月9日电，香港交易所披露信息显示，CitigroupInc.（花旗集团）在恒瑞医药的H股好仓（L）比例于10月5日从4.89%上升至5.24%。同时淡仓（S）比例从2.52%升至2.87%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610093891326438.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610093891326438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1267930227.SGD","600276","LU1969619763.USD","LU0072461881.USD","LU2328871848.SGD","LU0405327148.USD","LU0405327494.USD","LU0359201612.USD","BK0012","BK4559","01276","LU2543165471.USD","TFNS","LU1023057109.AUD","LU1074936037.SGD","LU1791807156.HKD","LU2462157665.USD","LU1064130708.USD","LU0477156953.USD","LU1997244956.HKD","LU1328615791.USD","LU1655091616.SGD","LU1201861249.SGD","LU1244550221.USD","LU0314106906.USD","LU2097828631.EUR","IYF","BK0183","LU1997245094.SGD","LU1255011170.USD","BK0028","FTXO","LU1997245177.USD","LU2360032135.SGD","BK4207","LU1162221912.USD","BK4585","LU0203347892.USD","BK4504","LU0980610538.SGD","LU1144417596.USD","LU2125154778.USD","LU0130102774.USD","BK4566","LU2125154935.USD","BK4534","LU2148510915.USD","LU1580142542.USD","BK0188","LU0106831901.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674885482","title":"阿斯利康两款重磅ADC药物在华获批新适应证；恒瑞医药第二款自主研发的创新药向欧盟递交上市申请丨医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2674885482","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674885482?lang=zh_cn&edition=full","pubTime":"2026-10-09 07:00","pubTimestamp":1791500422,"startTime":"0","endTime":"0","summary":"丨2026年10月9日星期五丨NO.1阿斯利康两款重磅ADC药物在华获批新适应证10月8日，阿斯利康宣布，由阿斯利康和第一三共联合开发和商业化的达卓优（通用名：注射用德达博妥单抗）于9月29日正式获得国家药监局批准，用于治疗不适合接受PD-1/PD-L1抑制剂治疗的不可切除或转移性三阴性乳腺癌成人患者。同日，阿斯利康还宣布，优赫得（通用名：注射用德曲妥珠单抗）也在中国获批。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610093890074039.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610093890074039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2495084118.USD","LU2097828805.USD","MEDX","LNGR","LU2289578879.USD","BK1161","LU1064131003.USD","159938","01276","LU0405327148.USD","LU2097828474.EUR","LU2543165471.USD","LU0359201885.HKD","LU2097828557.USD","LU1655091616.SGD","BK0028","IBBQ","BK0188","06978","BK0060","BK1515","LU1146622755.USD","LU1580142542.USD","LU1997245177.USD","LU2097828714.EUR","09939","LU1997244956.HKD","LU1255011170.USD","LU1064130708.USD","BK1191","LU0359202008.SGD","BK0183","LU2328871848.SGD","BK0239","159992","600276","LU1781817850.SGD","LU2488822045.USD","LU1328615791.USD","IPOS","BK1574","LU0405327494.USD","LU1997245094.SGD","BK0012","LU1969619763.USD","LU2580892862.HKD","LU2580892789.USD","LU2097828631.EUR","LU0359201612.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673787020","title":"恒瑞医药（01276）：氟唑帕利胶囊上市许可申请获欧洲药品管理局确认并受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2673787020","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673787020?lang=zh_cn&edition=full","pubTime":"2026-10-08 17:31","pubTimestamp":1791451908,"startTime":"0","endTime":"0","summary":"金吾财讯 | 恒瑞医药（01276）发布公告，近日，公司收到了欧洲药品管理局（简称“EMA”）的通知，EMA正式确认并受理公司递交的氟唑帕利胶囊的上市许可申请，这是公司第二款自主研发的创新药向欧盟递交上市申请。据介绍，本次申请的氟唑帕利联合醋酸阿比特龙和泼尼松或泼尼松龙拟用于治疗转移性去势抵抗性前列腺癌（mCRPC）成年患者。此前相关研究结果显示，试验组一线治疗mCRPC较对照组显着延长rPFS，差异具有统计学意义，且安全性可耐受。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/MmQyODg0ZTE3OGFjNmIzNjJjMjUzNzk5MzM4MDk2Mjc3OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmQyODg0ZTE3OGFjNmIzNjJjMjUzNzk5MzM4MDk2Mjc3OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993336","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359201612.USD","LU1781817850.SGD","LU1997244956.HKD","LU0405327148.USD","LU2097828631.EUR","LU1064131003.USD","LU1328615791.USD","BK0012","LU2289578879.USD","01276","LU2543165471.USD","LU1997245177.USD","LU1580142542.USD","LU0359201885.HKD","LU1655091616.SGD","LU1023057109.AUD","BK1191","LU1146622755.USD","LU1997245094.SGD","BK0060","LU0405327494.USD","LU2580892789.USD","LU2328871848.SGD","BK0239","LU2580892862.HKD","LU2097828474.EUR","LU1969619763.USD","LU2097828714.EUR","LU2488822045.USD","IPOS","LU1255011170.USD","LU2097828557.USD","BK0183","LU0359202008.SGD","BK0188","LU1820825898.SGD","BK0028","LU2495084118.USD","LU2097828805.USD","LU2148510915.USD","600276","LU1064130708.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673783140","title":"贝莱德在恒瑞医药的H股好仓比例上升0.71%至6.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673783140","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673783140?lang=zh_cn&edition=full","pubTime":"2026-10-08 17:20","pubTimestamp":1791451200,"startTime":"0","endTime":"0","summary":"南财智讯10月8日电，香港交易所披露信息显示，BlackRock,Inc.（贝莱德）在恒瑞医药的H股好仓（L）比例于10月5日从5.66%上升至6.37%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610083889710942.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610083889710942.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","600276","LU1997245094.SGD","LU1655091616.SGD","LU2580892789.USD","LU2289578879.USD","LU1969619763.USD","BK0239","LU1997244956.HKD","LU1328615791.USD","LU1997245177.USD","01276","BK1191","LU2097828631.EUR","BK0196","LU0359201885.HKD","LU1580142542.USD","LU1781817850.SGD","LU1023057109.AUD","BK0060","LU2328871848.SGD","LU2097828714.EUR","LU0359201612.USD","LU1064130708.USD","LU0359202008.SGD","LU2148510915.USD","LU0405327494.USD","LU1064131003.USD","LU2488822045.USD","LU1255011170.USD","LU2097828805.USD","LU1820825898.SGD","LU2495084118.USD","BK0183","LU0405327148.USD","LU2097828474.EUR","BK0012","LU2543165471.USD","LU2580892862.HKD","LU1146622755.USD","LU2097828557.USD","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673020996","title":"恒瑞医药(01276)截至9月末累计回购58.5万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2673020996","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673020996?lang=zh_cn&edition=full","pubTime":"2026-10-08 17:12","pubTimestamp":1791450730,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，截至2026年9月30日，公司本次股份回购方案累计通过上海证券交易所交易系统以集中竞价交易方式回购A股股份58.5万股，已回购股份占公司总股本的比例为0.009%，购买的最高价为人民币45.54元/股，最低价为人民币43.10元/ 股，已支付的总金额为人民币2587.59万元(不含交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201612.USD","83188","02823","LU1781817850.SGD","LU1997244956.HKD","83130","LU2097828631.EUR","LU1064131003.USD","LU1328615791.USD","BK0012","LU2289578879.USD","01276","LU2543165471.USD","LU1997245177.USD","LU1580142542.USD","LU0359201885.HKD","LU1655091616.SGD","07233","LU1023057109.AUD","02846","03130","LU1146622755.USD","LU0405327494.USD","LU2580892789.USD","159982","BK1610","LU2580892862.HKD","399300","LU2097828474.EUR","LU1969619763.USD","82822","LU2097828714.EUR","LU2488822045.USD","02843","82843","02822","82846","03188","LU1255011170.USD","LU2097828557.USD","BK0183","82823","02827","BK0028","LU2495084118.USD","LU2097828805.USD","LU2148510915.USD","600276","LU1064130708.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673023185","title":"大行评级丨小摩：恒瑞医药正加强免疫学业务发展，维持“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2673023185","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673023185?lang=zh_cn&edition=full","pubTime":"2026-10-08 13:59","pubTimestamp":1791439178,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["600276","LU1969619763.USD","LU2328871848.SGD","LU0405327148.USD","LU2580892862.HKD","LU0405327494.USD","LU0359201612.USD","BK0012","01276","LU2543165471.USD","LU1023057109.AUD","LU2097828805.USD","LU1064130708.USD","LU2097828557.USD","LU1997244956.HKD","LU1064131003.USD","LU1328615791.USD","LU1655091616.SGD","LU2097828631.EUR","LU0359202008.SGD","LU1820825898.SGD","LU0359201885.HKD","BK0183","BK0196","LU1781817850.SGD","LU2488822045.USD","LU1997245094.SGD","LU1255011170.USD","LU2097828714.EUR","BK0028","LU2580892789.USD","LU1997245177.USD","BK0060","LU1146622755.USD","BK0239","LU2148510915.USD","LU2495084118.USD","LU1580142542.USD","BK1191","LU2289578879.USD","BK0188","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673962310","title":"小摩：维持恒瑞医药“增持”评级 目标价65港元 EADV数据反映公司加强免疫学业务发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2673962310","media":"同花顺","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673962310?lang=zh_cn&edition=full","pubTime":"2026-10-07 16:14","pubTimestamp":1791360840,"startTime":"0","endTime":"0","summary":"摩根大通发布研报称，维持恒瑞医药(01276)“增持”评级及目标价65港元。恒瑞医药近日在欧洲皮肤病与性病学会(EADV)会议上发表多项研究，为其新兴免疫学产品线提供更广泛验证，涉及银屑并结 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261007/c680447408.shtml","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261007/c680447408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673098737","title":"恒瑞医药（01276）由跌转涨逾1% 小摩料其明年将有至少4款免疫学管线药物获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2673098737","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673098737?lang=zh_cn&edition=full","pubTime":"2026-10-07 14:10","pubTimestamp":1791353440,"startTime":"0","endTime":"0","summary":"金吾财讯 | 恒瑞医药 早盘曾跌超2.4%，午后转涨，逆市升逾1%，截至发稿，最新报49.06港元，涨幅1.36%。展望未来，摩通憧憬恒瑞明年将有至少有4款免疫学管线药物获批，并有多个项目进入第三期临床试验，其中核心项目SHR-1139或于今年内启动中国及全球三期试验，若进行全球三期临床试验，将是中国公司在免疫学领域最大规模的全球三期试验。该行维持恒瑞医药“增持”评级及目标价65元。","market":"hk","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993224","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IXG","LU2756315318.SGD","BK0196","LU1119994496.HKD","LU2430703095.HKD","LU0265550946.USD","LU1580142542.USD","LU2168564495.EUR","LU0345769128.USD","IE00BJTD4V19.USD","LU2505996681.GBP","JPO","LU1997245094.SGD","LU2237443978.SGD","FTXO","BK4207","LU0820561909.HKD","IE00B1XK9C88.USD","LU1064131342.USD","LU2244417387.USD","LU0323591593.USD","TRUF","IE00BLSP4239.USD","LU0320765489.SGD","LU2237443622.USD","UYG","FNCL","LU1548497426.USD","LU0787776722.HKD","LU2357305700.SGD","LU0208291251.USD","LU2264538146.SGD","LU2495084118.USD","VFH","LU0359202008.SGD","IE00BJLML261.HKD","XLF","JPMO","IYG","LU0683600562.USD","LU1820825898.SGD","BK4504","600276","LU2357627491.SGD","IE00BN8TJ469.HKD","IYF","TFNS","LU0345769631.USD","01276","KBWB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672471570","title":"瑞银集团在恒瑞医药的H股好仓比例下降0.58%至4.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2672471570","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672471570?lang=zh_cn&edition=full","pubTime":"2026-10-02 18:00","pubTimestamp":1790935220,"startTime":"0","endTime":"0","summary":"南财智讯10月2日电，香港交易所披露信息显示，UBSGroupAG（瑞银集团）在恒瑞医药的H股好仓（L）比例于9月25日从5.17%下降至4.59%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610023888367752.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610023888367752.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","LU0359202008.SGD","BK0188","LU2097828714.EUR","LU2097828631.EUR","LU2580892789.USD","BK0196","LU2328871848.SGD","LU1580142542.USD","LU0359201612.USD","LU1997245177.USD","LU2148510915.USD","BK0012","600276","BK1191","LU0359201885.HKD","LU1064130708.USD","LU0405327148.USD","LU2488822045.USD","LU2543165471.USD","BK0028","LU2097828474.EUR","01276","LU2580892862.HKD","BK0060","LU1255011170.USD","LU1997245094.SGD","LU1820825898.SGD","LU2097828557.USD","LU2097828805.USD","LU1064131003.USD","LU1655091616.SGD","LU1969619763.USD","LU1328615791.USD","LU1997244956.HKD","LU2495084118.USD","LU2289578879.USD","LU1146622755.USD","LU1781817850.SGD","BK0239","LU0405327494.USD","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671208625","title":"16股今日获机构买入评级 5股上涨空间超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671208625","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671208625?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:29","pubTimestamp":1790760540,"startTime":"0","endTime":"0","summary":"16只个股今日获机构买入型评级，千禾味业最新评级被调高，财通证券、航亚科技、美的集团为机构首次关注。证券时报·数据宝统计显示，今日机构研报共发布16条买入型评级记录，共涉及16只个股。今日获机构买入型评级个股中，共有5条评级记录中对相关个股给出了未来目标价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/11134,202609303887789341.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/11134,202609303887789341.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["LU2580892789.USD","BK0012","LU1580142542.USD","LU2097828474.EUR","BK0183","BK1191","BK0239","LU2097828714.EUR","01276","LU1255011170.USD","LU1146622755.USD","LU1064130708.USD","600276","LU1328615791.USD","LU1997245177.USD","LU1969619763.USD","LU2543165471.USD","LU2148510915.USD","LU1064131003.USD","LU1781817850.SGD","LU2097828631.EUR","BK0188","LU2580892862.HKD","LU2328871848.SGD","LU2495084118.USD","LU0405327148.USD","LU2289578879.USD","LU2488822045.USD","LU0359201612.USD","LU2097828805.USD","LU0359201885.HKD","BK0028","LU1997245094.SGD","LU1820825898.SGD","LU1997244956.HKD","BK0060","LU1655091616.SGD","LU2097828557.USD","LU0405327494.USD","LU0359202008.SGD","BK0196","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671748782","title":"大和：恒瑞医药(01276)与诺和诺德就HRS-1596达许可协议 交易总额及预付款均具吸引力","url":"https://stock-news.laohu8.com/highlight/detail?id=2671748782","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671748782?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:13","pubTimestamp":1790756039,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，大和发布研报称，恒瑞医药已与诺和诺德就HRS-1596达成授权协议，交易总值26亿美元，包括3亿美元预付款。诺和诺德将取得在中国以外市场开发、生产及商业化HRS-1596的独家权利。该行认为，此次外授交易令人印象深刻，原因包括这是恒瑞首次将GLP-1产品外授予顶级跨国药企，更重要的是诺和诺德为全球两大GLP-1领导者之一；同时交易总额及预付款均具吸引力。该行相信，诺和诺德的认可反映出其对恒瑞自主研发、口服每周一次HRS-1596潜力的信心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502607.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","LU1328615791.USD","LU2580892862.HKD","LU0359202008.SGD","LU2328871848.SGD","LU2495084118.USD","LU2097828805.USD","LU2148510915.USD","BGIA","LU2097828557.USD","BK0183","BK0060","LU1064131003.USD","LU2289578879.USD","LU2097828714.EUR","LU1146622755.USD","LU1064130708.USD","600276","BK1191","LU2543165471.USD","LU1023057109.AUD","BK0196","LU0359201885.HKD","LU1997244956.HKD","LU2488822045.USD","BK0239","LU1655091616.SGD","LU2097828631.EUR","BK0028","01276","LU1255011170.USD","BK0188","LU0405327494.USD","LU1781817850.SGD","LU2097828474.EUR","LU0405327148.USD","LU1997245177.USD","LU1820825898.SGD","LU1969619763.USD","LU1580142542.USD","LU0359201612.USD","LU1997245094.SGD","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671754842","title":"大摩：维持恒瑞医药(01276)“增持”评级 目标价82港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671754842","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671754842?lang=zh_cn&edition=full","pubTime":"2026-09-30 14:45","pubTimestamp":1790750717,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利发布研报称，维持恒瑞医药(01276)目标价82港元以及“增持”评级。该行表示，每周一次口服领域仍非常早期，全球竞争者数目有限。3亿美元首付款对一个仍属IND/Phase 1阶段的资产而言属“相当可观”。交易再次反映全球药企仍高度重视肥胖症市场;恒瑞GLP-1平台具全球竞争力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600276","EWH","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671273382","title":"花旗：上调恒瑞医药目标价至120港元 仍是重点推荐之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2671273382","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671273382?lang=zh_cn&edition=full","pubTime":"2026-09-30 14:05","pubTimestamp":1790748300,"startTime":"0","endTime":"0","summary":"花旗发布研报称，将恒瑞医药(01276)(600276.SH)H股及A股目标价分别由119港元及109元人民币，调高0.8%及1.8%至120港元及111元人民币，恒瑞医药仍是该行首选的重点推荐标的之一。恒瑞医药与诺 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260930/c680401730.shtml","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260930/c680401730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671294288","title":"诺和诺德加仓减重赛道，26亿美元买下恒瑞医药周口服减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=2671294288","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671294288?lang=zh_cn&edition=full","pubTime":"2026-09-29 15:58","pubTimestamp":1790668739,"startTime":"0","endTime":"0","summary":"在2030战略目标未能打动资本市场背景下，诺和诺德转身加码并购减肥药管线。9月29日中午，恒瑞医药（600276.SH；01276.HK）宣布已与诺和诺德达成许可协议，将胰高血糖素样肽-1（GLP-1）和抑胃肽（GIP）双受体激动剂HRS-1596海外开发、生产和商业化独家权利授权给诺和诺德。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609293886468670.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609293886468670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1781817850.SGD","LU2580892789.USD","LU2097828474.EUR","BGIA","01276","LU1328615791.USD","LU0359201885.HKD","BK0028","LU2097828714.EUR","LU1997244956.HKD","BK0239","BK0060","LU2097828805.USD","BK0196","LU1997245094.SGD","BK0188","LU2097828557.USD","LU1655091616.SGD","LU1023057109.AUD","LU0359201612.USD","LU2148510915.USD","LU1969619763.USD","LU0405327148.USD","LU2328871848.SGD","BK0012","LU2543165471.USD","LU2289578879.USD","THNR","LU2488822045.USD","LU2097828631.EUR","LU2495084118.USD","LU1064131003.USD","LU0359202008.SGD","LU1255011170.USD","LU1064130708.USD","LU1580142542.USD","LU1820825898.SGD","LU2580892862.HKD","BK1191","LU1146622755.USD","600276","LU0405327494.USD","LU1997245177.USD","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671293387","title":"加速出海！恒瑞医药口服GLP-1/GIP减重药授权诺和诺德，潜在交易额最高26亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671293387","media":"华尔街见闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671293387?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:26","pubTimestamp":1790659609,"startTime":"0","endTime":"0","summary":"恒瑞医药股价直线拉升超3%，公司将自主研发的口服GLP-1/GIP双受体激动剂HRS-1596授权给诺和诺德，交易包括3亿美元首付款及最高23亿美元里程碑付款，并另收销售提成。HRS-1596有望实现每周一次口服给药，目前仍处早期临床阶段。恒瑞预计该交易将于2026年第四季度完成交割。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3782716","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","LU0359202008.SGD","BK0188","LU2097828714.EUR","LU2097828631.EUR","LU2580892789.USD","BK0196","LU2328871848.SGD","LU1580142542.USD","LU0359201612.USD","LU1997245177.USD","LU2148510915.USD","BK0012","600276","BK1191","LU0359201885.HKD","LU1064130708.USD","LU0405327148.USD","LU2488822045.USD","LU2543165471.USD","BGIA","BK0028","LU2097828474.EUR","01276","LU2580892862.HKD","BK0060","LU1255011170.USD","LU1997245094.SGD","LU1820825898.SGD","JDOC","LU2097828557.USD","LU2097828805.USD","LU1064131003.USD","LU1655091616.SGD","LU1969619763.USD","LU1328615791.USD","LU1997244956.HKD","LU2495084118.USD","LU2289578879.USD","LU1146622755.USD","LU1781817850.SGD","BK0239","LU0405327494.USD","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792037354430,"stockEarnings":[{"period":"1week","weight":-0.0362},{"period":"1month","weight":0.0542},{"period":"3month","weight":-0.1875},{"period":"6month","weight":-0.1891},{"period":"1year","weight":-0.2893},{"period":"ytd","weight":-0.2332}],"compareEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":-0.0304},{"period":"3month","weight":-0.0297},{"period":"6month","weight":-0.0701},{"period":"1year","weight":-0.0254},{"period":"ytd","weight":-0.0508}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"539148人(较上一季度增加17.64%)","perCapita":"11831股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":" 江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是注射用卡瑞利珠单抗、羟乙磺酸达尔西利片、瑞维鲁胺片、海曲泊帕乙醇胺片、脯氨酸恒格列净片、碘佛醇注射液。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}